The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.
Fuente : http://www.eurekalert.org/pub_releases/2013-06/uop...
Fuente : http://www.eurekalert.org/pub_releases/2013-06/uop...